Problem Statements
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-01
Develop a reinforcement learning-based algorithm to identify lead molecules by emulating ligand-protein interactions
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-02
Machine learning models to prioritize optimal parameters of predicted ADME and Toxicity data
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-03
Building SARS-CoV-2 Inhibitor Knowledgebase – SAVIOR
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-04
Machine intelligence design and development of main protease inhibitors drugs.
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-05
To develop a regression based QSPR model for Caco-2 cell permeability.
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-06
Predicting the biological properties of potential SARS-CoV-2 inhibitors using graph theory and machine learning
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-07
ML model to predict small molecule clinical trial success probability by phase
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-08
Matched Pair Analysis based tool to generate isosteric and bioisosteric molecular libraries
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-09
Automated Analogue library generation tool using bioisosteres
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-10
ML model for antiviral peptide predictions using Generative Adversarial Networks
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-11
Implement a framework to mine protein-ligand & protein-protein interaction networks for drug repurposing
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-12
To improve the efficiency of MOLS algorithm in terms of sampling, scoring and computational time
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-13
Developing a linear discriminant analysis model for screening pharmaceutical compounds with hERG inhibitory activity (cardiotoxicity) and using the model to screen CAS antiviral database to identify compounds with cardiotoxicity potential
Category : T2 - General Drug Discovery, Including COVID
PS ID : DDT2-14